Overview

IBI is focused on developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market.  IBI’s lead portfolio product, IBI-10090, is currently in late stage clinical trials. A New Drug Application (NDA) is planned for late 2015.

Categories

Disclaimer

My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.